5 February 2019

Jack Schalken and Vicky Luna Velez and colleagues, theme Urological cancers, published in Oncogene about suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis.

Publication in Oncogene: link.
Jack Schalken
Vicky Luna Velez

One of the mechanisms by which advanced prostate cancer develops resistance to androgen deprivation therapy is the elevated expression of C-terminally truncated androgen receptor (AR) variants. These variants, such as AR-V7, originate from aberrant splicing of the AR pre-mRNA and the inclusion of a cryptic exon containing a premature stop codon in the mRNA. The resulting loss of the ligand-binding domain allows AR-V7 to act as a constitutively active transcription factor. They designed two antisense oligonucleotides (AONs) directed against cryptic splicing signals within the AR pre-mRNA. These two AONs, AON-ISE and AON-ESE, demonstrated high efficiency in silencing AR-V7 splicing without affecting full-length AR expression. The subsequent downregulation of AR-V7-target gene UBE2C was accompanied by inhibition of androgen-independent cell proliferation and induction of apoptosis in castration-resistant prostate cancer (CRPC)-derived cell line models 22Rv1, DuCaP, and VCaP.
 
Their results show that splicing-directed AONs can efficiently prevent expression of AR-V7, providing an attractive new therapeutic option for the treatment of CRPC (castration-resistant prostate cancer).
 

Related news items


H2020 Grant for Frank Walboomers and Ronald Bartels

23 May 2019

Frank Walboomers and Ronald Bartels, theme Reconstructive and regenerative medicine, have received a € 500,000 grant for research into graphene biomaterials from the Europan Union Horizon 2020 FET Open programme.

read more

Innovation Grant Dutch Kidney Foundation for Jeroen de Baaij

23 May 2019

Jeroen de Baaij, theme Renal disorders, was awarded with an Innovation Grant of the Dutch Kidney Foundation. Jeroen's research proposal was selected from a competitive field of innovative approaches to treat kidney disease.

read more

Graduate school news Adjusted PhD guidelines

23 May 2019

It should be emphasized that the quality, and not the number of chapters, determines the assessment by the manuscript committee. To avoid the wrong emphasis on quantity, it is not recommended to have more than three publishable chapters in the thesis.

read more

Rob ter Horst in Dutch television broadcast Brandpunt Plus

21 May 2019

In a Dutch television broadcast, called Brandpunt Plus, Rob ter Horst, PhD candidate, theme Infectious diseases and global health, explains how he records data about himself and what he hopes to find out about himself.

read more

A personal touch of Jelle Zwaag

19 May 2019

In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Jelle Zwaag.

read more

How do we keep new technology affordable to improve the lives of people?

16 May 2019

Improving healthcare by means of new technological developments? We need to change the entire approach for evaluating the true impact , says Maroeska Rovers. By bringing together all stakeholders from the beginning, millions of euros can be saved.

read more